Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.

Thoracic cancer - 1 Feb 2022

Yin Qiang, Guo Taiyan, Zhou Yangyang, Sun Leina, Meng Maobin, Ma Li, Wang Xiaoguang

Abstract excerpt

The echinoderm microtubule associated protein-like 4 gene (EML4) encodes the predominant anaplastic lymphoma kinase (ALK) fusion partner in non-small-cell lung cancer (NSCLC); however, the dynactin subunit 1 (DCTN1)-ALK rearrangement is extremely rare. The co-occurrence of primary epidermal growth factor receptor (EGFR) T790M mutation with EGFR exon 19 deletion (del) in patients with NSCLC is uncommon. Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Aniline Compounds

Share to Carbazoles

Share to Dynactin Complex

Share to Piperidines

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34964276
DOI: 10.1111/1759-7714.14291
PMCID: PMC8841708

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.PMID 34964276Read ↗

A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.Semantic proximity Read ↗

A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy.Semantic proximity Read ↗

A Novel ALK Gene Mutation and Its Response to Second-Generation TKIs: a Case Report and Literature ReviewSemantic proximity Read ↗

Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.Semantic proximity Read ↗

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.Semantic proximity Read ↗

Effective Treatment With Endostar and Crizotinib Sequential Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases Harboring a Novel CLHC1/RNT4 Intergenic Region- ALK FusionSemantic proximity Read ↗

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma: a rare EGFR alteration reportSemantic proximity Read ↗

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.Semantic proximity Read ↗

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations.Semantic proximity Read ↗

Treatment of Alectinib in NSCLC with Brain Metastasis Patient Refractory to Radiotherapy after Resistance to Crizotinib: A Case Report and Literature ReviewSemantic proximity Read ↗

A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.